Quantcast

Latest Exosome Diagnostics Stories

2014-08-04 08:27:53

-Company moves headquarters to Cambridge, Mass. - CAMBRIDGE, Mass., Aug. 4, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced the appointment of Thomas McLain as its chief executive officer, effective July 23, 2014. The company is also announcing the relocation of its headquarters to Cambridge, Mass. "I am very pleased that Exosome Diagnostics has been able to attract Tom, a proven leader with a...

2014-06-03 08:32:14

NEW YORK, June 3, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalized medicine, most recently as global head Personalized of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalized medicine...

2014-05-28 08:31:28

NEW YORK, May 28, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that William J. Kelly has been appointed as its chief financial officer, effective May 27, 2014. Mr. Kelly, 43, has over 20 years of financial management experience, including the past 13 years leading growing, international, publicly traded life science companies. For the past six years, Mr. Kelly worked at RepliGen Corporation,...

2014-03-11 08:29:02

NEW YORK, March 11, 2014 /PRNewswire/ -- Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas. Key Points: -- Co-leading the financing were new investors QIAGEN and Arcus Ventures --...

2014-01-13 04:20:53

-- Collaboration will focus on enabling detection of known cancer biomarkers in blood plasma NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of...

2013-08-21 23:21:31

Under the agreement, Mount Sinai will retain rights to molecular biomarkers associated with disease progression and drug response, and Exosome Diagnostics will retain commercial development rights for molecular in vitro diagnostic products. New York, NY (PRWEB) August 21, 2013 The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics today announced a collaboration on the research and development of real-time nucleic acid-based body-fluid diagnostics to advance personalized...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related